SynCell Biotechnology mission is to unlock the potential of Microbiology and Green Nanotechnology in the creation of nanomaterials produced by bacteria.
Our mission is to bring real solutions to the biomedical world in the fight of some of the most worrisome healthcare concerns.
Using bacteria as biofactories, our core technology allows us to produce environmentally-friendly and safe nanomaterials with antimicrobial, anticancer and antoxidant properties with great potential in the biomedical field
David Medina enters as a PhD at the Chemical Engineering Department at Northeastern university, where he created The Green Chemistry Lab, a research division focused on the use of Green Nanotechnology in the biomedical field.
David Medina publish a paper showing the promise of the technology and envision the potential of the project, which is patented
Ada Vernet join the lab to pursue a master degree, and start working with David in the project. The technology start getting interest among the community as David starts taking the project to different conferences all over the world.
The team continues growing with Junjiang Chen. Who joins the lab to pursue also a master degree while helps with the project development.
Driven by advice in the community, the project is taken into consideration for its commercial applicability and is evaluated through the NSF iCORPs program in an extensive customer discovery process. Alfredo Cabañero joins the team providing a business-oriented vision.
SynCell Biotechnology, Inc. is registered as a C-Corps in the state of Delaware.
SynCell’s core values are built over what we consider are the three foundations of our entire structure, mission, and vision, which determine and influence every step and direction we take, from the most simple analytical thinking to the most complex business decision:
Quality in innovation. We seek to bring the best of the intersection between microbiology and nanotechnology in the shape of products with great potential to tackle the most compelling healthcare concerns.
The greenway. We seek to incorporate the principles of Green Nanotechnology to every step of processing our technology, presenting cost-effective and environmentally-friendly approaches that are respectful to both society and nature.
The value of people. Above everything else, standard or value, is our people: those who work with us and those who we serve with our products.
What is the problem we are trying to solve?Admin2020-08-16T11:04:48+00:00
One of the biggest challenges that we are fighting is the rise and development of antimicrobial resistance to antibiotics(AMR). Each year in the U.S., almost 3 million people get an antibiotic-resistant infection, and more than 35,000 people die. Fighting this healthcare threat is a public health priority and one of the main commitments of our company.
Why are we doing this?Admin2020-08-16T11:05:11+00:00
Every day someone lost a relative or close friend to AMR when the antibiotics treatment failed due to the development of resistance.
It is the moment to step up and say“no more”. We, SynCell, were committed to seeking a future where antibiotics’ failure will not leave us with empty hands and a painful time to mourn for the unavoidable. We work to produce an alternative solution, and bring those suffering not just another option, but one that works.
How are we tackling this problem?Admin2020-08-16T11:05:30+00:00
At SynCell, we believe that the solution towards AMR is not in the form of traditional antibiotics, the reason why we decided to seek the best approach in the problem itself: bacteria.
By understanding the mechanisms of important biochemical processes in prokaryotic cells, we use bacteria as biofactories of nanomaterials without introducing any genetic manipulation in the organisms. Once produced, the nanomaterials are purified and employed as either sole antimicrobials or key components in combinatorial medical devices.
What is our targeted market?Admin2020-08-16T11:06:04+00:00
At SynCell, we believe that to achieve greatness, we do have to start small, reason why we have gathered as many features of our technology, and packed them in a product pipeline that we expect to release as soon as possible.
Our initial portfolio of products is composed by SYN-BC, a family of antimicrobial dressings to treat open wounds that are either prompt or already infected with bacteria.